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ABSTRACT
Osteoblasts and adipocytes differentiate from a common precursor cell, the mesenchymal stem cell (MSC). Adenosine is known to signal
via four adenosine receptor subtypes, and significantly, recent findings indicate that these may play a role in MSC differentiation. We
therefore investigated adenosine receptor expression and activation during the differentiation of MSCs to osteoblasts and adipocytes.
The A2BR was dominant in MSCs, and its expression and activity were transiently upregulated at early stages of osteoblastic
differentiation. Both activation and overexpression of A2BR induced the expression of osteoblast-related genes [Runx2 and alkaline
phosphatase (ALP)], as well as ALP activity, and stimulation increased osteoblast mineralization. The expression of A2AR was upregulated
during later stages of osteoblastic differentiation, when its activation stimulated ALP activity. Differentiation of MSCs to adipocytes was
accompanied by significant increases in A1R and A2AR expression, and their activation was associated with increased adipogenesis.
Enhanced A2AR expression was sufficient to promote expression of adipocyte-related genes (PPARg and C/EBPa), and its activation
resulted in increased adipocytic differentiation and lipid accumulation. In contrast, the A1R was involved mainly in lipogenic activity of
adipocytes rather than in their differentiation. These results show that adenosine receptors are differentially expressed and involved in
lineage-specific differentiation of MSCs. We conclude, therefore, that fruitful strategies for treating diseases associated with an imbalance
in the differentiation and function of these lineages should include targeting adenosine receptor signal pathways. Specifically,
these research avenues will be useful in preventing or treating conditions with insufficient bone or excessive adipocyte formation.
 2011 American Society for Bone and Mineral Research.
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Introduction
Osteoporosis and obesity are currently major healthproblems worldwide and, furthermore, are growing in
prevalence. They are both disorders of body composition, and
while they were once thought to be mutually exclusive, they are
now thought to be closely related and to share several
features.(1,2) One of these shared features is that osteoblasts
and adipocytes differentiate from a common precursor cell in the
bone marrow, the mesenchymal stem cell (MSC). The pluripo-
tency of MSCs is well known, and their ability to differentiate into
osteoblasts, adipocytes, chondrocytes, and myoblasts has been
described extensively.(3) Although numerous studies(4–7) have
shown that many substances, as well as mechanical agents,
contribute to these differentiation processes, the mechanisms
involved are yet to be completely defined. There is, however, a
large body of evidence to support the notion that there is an
inverse relationship between the differentiation of MSCs to
osteoblasts and adipocytes. This seems to be true during
attainment of peak bone mass(8,9) and in an aging population.(10)
Furthermore, such a relationship has been shown in individuals
with high bone mass(11) and following mechanical loading,(12)
whereas secondary causes of osteoporosis (eg, diabetes,
glucocorticoids, and immobility) are associated with bone
marrow adiposity.(1)
Adenosine receptors exist as four subtypes, A1R, A2AR,
A2BR, and A3R, that signal through primarily the stimulation
(A2AR and A2BR) and inhibition (A1R and A3R) of cyclic adenosine
monophosphate (cAMP) and are possible drug targets for many
diseases, including osteoporosis.(13) We recently described the
expression and function of adenosine receptors in a human
osteoprogenitor cell line and in primary bone marrow MSCs and
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showed that A2BR is functionally dominant in these cells.
(14) We
also showed that adenosine has a potent stimulatory action on
interleukin 6 (IL-6) release and an inhibitory action on
osteoprotegerin expression, suggesting that adenosine recep-
tors are regulators of MSC differentiation, as well as bone
formation and resorption.(14)
Adenosine receptors, in particular, A2AR, have been shown to
mediate anti-inflammatory actions and have been implicated in
tissue repair and damage.(15–18) A2AR has been shown recently
to be involved in the proliferation and differentiation of
murine bone marrow–derived MSCs.(19) A2Rs are also
expressed on preadipocytes, whereas A1R is expressed pre-
dominantly on mature adipocytes.(20,21) Furthermore, it is known
that A1R activation mediates leptin secretion
(22) and protects
against obesity-related insulin resistance.(23)
In this study we investigated the expression of the adenosine
receptor subtypes, as well as adenosine metabolic and catabolic
enzymes, in MSCs as they differentiated to osteoblasts and
adipocytes. Furthermore, we used receptor agonists and
antagonists, as well as receptor overexpression, to dissect out
the role of the receptor subtypes during these differentiation
processes.
Materials and Methods
Materials
General and cell culture materials were from Sigma-Aldrich
(Poole, Dorset, UK), Fisher Scientific (Loughborough, UK), Lonza
(Slough, UK), Biosera (Ringmer, UK), and Invitrogen (Paisley, UK).
Molecular biology reagents were from Promega UK Ltd.
(Southampton, UK) or as indicated. Antisera were obtained
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), Abcam
(A1R, A2aR, and A3R; Cambridge UK), and Alpha Diagnostic
International (A2bR; San Antonio, TX, USA).
Adenosine receptor agonists and antagonists (Tocris Biosci-
ence, Avonmouth, Bristol, UK) were universal agonists, adeno-
sine, and 5’-N-ethylcarboxamidoadenosine (NECA); A1R agonist
and antagonist, 2-chloro-N6-cyclpentyladenosine (CCPA) and
1-butyl-8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-
dihydro-3-(3-hydroxypropyl)-1H-purine-2,6-dione (PSB36); A2AR
agonist and antagonist, 3-[4-[2-[6-amino-9-[(2R,3R,4S,5S)-5-
(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]
phenyl]propanoic acid (CGS21680) and 2-(2-furanyl)-7-[3-(4-
methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidin-5-amine (SCH442416); and A2BR antagonist, N-(4-
acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-
purin-8-yl)penoxy]-acetamide (MRS1706).
The natural adenosine receptor agonist adenosine is rapidly
metabolized in cell culture environments; thus this work relies on
the use of the more stable adenosine receptor agonist NECA,
although results with adenosine are also discussed where
possible. Furthermore, since a subtype-specific A2B agonist is
not currently available commercially for use, we have used
throughout this study a universal adenosine receptor agonist
(NECA), a specific A2A receptor agonist (CG62180), and
specific A2A and A2B receptor antagonists (SCH442416 and
MRS1706, respectively) to dissect out the roles of the A2A and A2B
receptors in MSC differentiation. Thus we have characterized A2B
receptors by relying on the lack of effectiveness of compounds
that are potent and selective agonists of other receptor types.
Cell culture
Rat bone marrow MSCs resuspended in normal growth
medium—a-minimal essential medium (a-MEM) L-glutamine
(2mM), penicillin (50 U/mL), streptomycin (50mg/mL), and 10%
fetal bovine serum (FBS)—were plated (2 106 cells/cm2) in 75-
cm2 flasks and incubated at 378C in 5% CO2 and 95% air for 3
days. The medium then was changed to remove nonadherent
cells and again every 3 to 4 days thereafter, and the cells were
used at passages 0 to 3.
For osteoblast differentiation, cells were seeded (5 103 cells/
cm2) in normal growth medium, and 24 hours later, differentia-
tion was induced with L-ascorbic acid 2-phosphate (50mg/mL)
and dexamethasone (108M). For mineralization experiments, b-
glycerol phosphate (2mM) also was added. For adipocyte
differentiation, MSCs were cultured in normal growth medium
until 50% confluent, and adipogenic differentiation was induced
with dexamethasone (108M), indomethacin (60mM), and
insulin (10mg/mL). For most experiments, the medium was
replenished every 2 to 3 days. For mineralization experiments
involving adenosine, the medium was changed every weekday.
Quantitative real-time polymerase chain reaction (qPCR)
Total RNA was prepared using TRIzol (Invitrogen), and
contaminating DNA was removed using the TURBO DNA Free
Kit (Applied Biosystems, Warrington, UK). cDNA was prepared
from 1mg of RNA by incubation for 1 hour at 378C with Moloney
Murine Leukemia Virus reverse transcriptase, RNasin, deoxyribo-
nucleotide triphosphate mix, and oligodeoxythymidilic acid
[oligo(dT)15]. qPCRwas performed on anMX3000P thermal cycler
(Stratagene, La Jolla, CA, USA). Each reaction contained SYBR
Green Master Mix (12.5mL; Stratagene), primer mix (1mL;
10 pmol of each primer, Table 1), cDNA template (1mL), and
nuclease-free water (10.5mL). The program (40 cycles) consisted
of 908C (30 seconds), 608C (1 minute), and 728C (30 seconds). b-
Actin was used as an invariant housekeeping gene. The relative
quantitative expression of the gene of interest (GOI) relative to b-
actin was calculated, and this ratio for basal or untreated cells
was assigned a value of 1.
Western blotting
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer
(50mM Tris, pH 7.5, 150mMNaCl, 1% Nonidet P-40, 0.1% sodium
dodecyl sulfate, and 0.5% sodium deoxycholate) containing
protease inhibitors cocktail solution (chymostatin, leupeptin,
antipain, and pepstatin all at 10mg/mL), 1mM sodium
orthovanadate, and 0.1mg/mL of phenylmethylsulfonyl fluoride
(PMSF). Protein concentrations were quantified with the Bio-Rad
protein assay (Bio-Rad Laboratories, Ltd., Hertfordshire, UK).
Lysates (15 to 30mg of protein) and prestained protein markers
(Cell Signaling Technology, Beverly, MA, USA) were mixed with
an equal volume of loading buffer (4% sodium dodecyl sulfate,
2% b-mercaptoethanol, 20% glycerol, 100mM Tris-HCl, pH 6.8,
and 0.004% pyronin Y) and subjected to SDS-PAGE. Proteins
ADENOSINE AND MSC DIFFERENTIATION Journal of Bone and Mineral Research 2113
were transferred onto polyvinylidene fluoride (PVDF) mem-
branes and incubated overnight at 48C with specific antisera
(used at the recommended concentrations, usually 1:1000 or
1:2000). Secondary antibodies (1:5000) conjugated with horse-
radish peroxidase were applied for 1 hour at room temperature,
and proteins were visualized with ECL Plus reagent. Blots were
stripped and reprobed with anti-b-actin (1:1000) for 1 hour at
room temperature. Band densities were calculated using an
AlphaImager documentation and analysis system (Alpha
Innotech Corporation, Santa Clara, CA, USA).
Alkaline phosphatase (ALP) activity assay
Alkaline phosphatase (ALP) activity was determined by an
assay based on the hydrolysis of p-nitrophenylphosphate to
p-nitrophenol (Sigma-Aldrich). Cells were washed with PBS, and
50mL of phosphatase substrate/alkaline buffer (pH 10.3) was
added to each well. After 20minutes in the dark, absorbance
(405 nm) was read on a SpectraCount microplate photometer
(Canberra Packard, Ltd., Oxfordshire, UK). ALP activity was
normalized to protein concentration in parallel experimental
plates.
Mineralization
Mineralized matrix was stained with alizarin red S (1:100 in
distilled water, adjusted to pH 4.2, and filtered). Cells were
washed with PBS, fixed (4% formaldehyde in PBS) for 15minutes,
washed with distilled water, stained for 10minutes, washed (five
times) in 50% ethanol, and air dried. For quantification,
cells were destained overnight in 10% (w/v) cetylpyridinium
chloride at room temperature with continuous agitation. The
absorbance (562 nm) was read using a SpectraCount microplate
photometer.
Oil red O and Nile red staining of adipocytes
Accumulation of intracellular lipid was assessed by staining with
oil red O — a 5% stock solution in isopropanol was used
to prepare the working solution of 3% in water.(24) Cells were
fixed (15minutes with 4% formaldehyde in PBS), stained for
15minutes, and then washed with 60% isopropanol and
PBS. Lipid accumulation was viewed microscopically, and
images were captured with a Penguin 150 CL camera (Pixera
Corporation, Santa Clara, CA, USA) through Viewfinder
3.0.1 (Pixera Corporation). For quantification, the dye was
extracted with 0.2mL of isopropanol (1 minute), and the
absorbance (490 nm) was read using a SpectraCount microplate
photometer.
Nile red (1mg/mL in dimethyl sulfoxide stock(24)) was diluted
1:100 in PBS immediately before use. Cells were trypsinized, fixed
for 30minutes (4% formaldehyde in PBS) at 48C, centrifuged,
resuspended in Nile red (1mL) for 30minutes at 48C, and
analyzed with a FACSCalibur flow cytometer (Becton Dickinson
Biosciences, Oxford, UK). For each sample, 15,000 events were
collected, and data were analyzed using CellQuest 3.1 software
(Becton Dickinson Biosciences).
Transient transfection of A1R, A2AR, and A2BR into MSCs
Gene constructs for human A1R, A2AR, and A2BR (kind gift from
KN Klotz, Institute for Pharmacology und Toxicology, University
of Wu¨rzburg, Wu¨rzburg, Germany) were cloned or subcloned
into the plasmid pcDNA3.1. MSCs were transfected using the
Human MSC Nucleofector Kit with the Nucleofector machine
(Lonza). Cells were trypsinized, and 5 105 cells were resus-
pended in 100mL of nucleofector solution and treated with 2mg
of pcDNA3.1/A1, pcDNA3.1/A2A, pcDNA3.1/A2B, pcDNA3.1 empty
vector (vector control), or positive control vector pmaxGFP to
monitor transfection efficiency. The cells were plated in 6-well
plates, and after overnight incubation, the mediumwas changed
and efficiency of transfection was determined by light and
fluorescence microscopy. RNA was prepared 48 hours after
nucleofection and subjected to qPCR analysis.
Statistical analysis
Statistical comparisons were determined using one-way ANOVA
(SPSS 16, SPSS, Inc., Chicago, IL, USA) and the Tukey multiple-
comparison test. Results were considered significant if p< .05.
Results
Undifferentiated MSCs
Initial experiments demonstrated that the A1R, A2AR, A2BR, and
possibly A3R (observed only at a Ct value of 35 or above) mRNA,
as well as adenosine metabolic and catabolic enzyme (ie,
adenosine deaminase, adenosine kinase, and CD73) mRNA, were
expressed in undifferentiated MSCs. Furthermore, Western
blotting showed that three receptor protein subtypes
(A1R, A2AR, and A2BR) were present, with the A3R not being
apparent (Fig. 1). In addition, a cAMP assay indicated that the A2B
subtype was predominant, although these assays did not
preclude the presence of other functional adenosine receptor
subtypes (results not shown). Furthermore, the A3R protein was
not detected, whereas MSCs underwent osteoblastic or
adipogenic differentiation, and at the same time there was no
convincing evidence of the presence of A3R mRNA during these
differentiation processes (Figs. 2D and 4D), Thus we did not
continue further with studies of the A3R in MSCs.
Fig. 1. Western blot analysis of adenosine receptor protein expression.
(A) Expression of A1R, A2AR, and A2BR proteins is indicated by dashed oval
shapes. Positive control (PC; BON-1) for the A3R protein is also shown. Left
margin indicates the sizes (kDa) of protein markers. (B) Western blot
analysis of BON-1 (lane 1) and KRJ-1 (lane 2) cell extracts (positive
controls) with A3R antibody. BON-1 and KRJ-1 are human neuroendo-
crine tumors derived from pancreas and intestine, respectively.
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Fig. 2. Expression and function of adenosine receptors during the differentiation of MSCs into osteoblasts. mRNA expression of (A) A1R, (B) A2AR, (C) A2BR,
(D) A3R, and (E) CD73 (mean SEM of three experiments in duplicate). ( F) Representative Western blots probed for A1R, A2AR, and A2BR. (G–I) cAMP
concentrations in MSCs differentiated to osteoblasts for 9 days and following incubation with (G) adenosine, (H) NECA, and (I) CGS21680 for 15minutes in
the presence of RO20-1724 (104M) (mean SEM of two experiments in quadruplicate). p< .05, p< .01, and p< .001 when compared with
untreated cells at day 0; ##p< .001 and ###p< .001 when compared with untreated cells at the same time point.
ADENOSINE AND MSC DIFFERENTIATION Journal of Bone and Mineral Research 2115
Adenosine receptor mRNA and protein expression during
osteoblastogenesis
During osteoblastogenesis, the mRNA expression of A1R (Fig. 2A)
was upregulated by up to eightfold between days 5 and 12,
whereas the A2AR (Fig. 2B) and A2BR (Fig. 2C) mRNA showed small
increases (twofold). Interestingly, A2BR mRNA expression also
appeared to decrease beyond day 7. No changes were observed
for A3R mRNA expression (Fig. 2D). CD73 mRNA decreased by
50% (p< .05) by day 2 of osteoblastic differentiation and then
progressively returned to levels seen in undifferentiated cells
(Fig. 2E). There were no changes in adenosine deaminase
expression during osteoblast differentiation.
In contrast to changes in A1R mRNA expression during
osteoblastogenesis, the A1R protein remained relatively un-
changed. A representative blot is shown in Fig. 2F, and
combining densitometric values from three separate experi-
ments confirmed that A1R protein expression did not change
significantly during differentiation to osteoblasts. This difference
may be related to the already high expression of the protein in
undifferentiated MSCs, which could limit further translation of
mRNA. Changes in A2AR protein expression were similar to those
seen with mRNA expression during differentiation. A relatively
faint protein band was detected in undifferentiated MSCs that
increased gradually in intensity during osteoblast differentiation
and was maximal at days 7 to 12. The A2BR protein expression
remained unchanged on day 1 but was strongly upregulated on
days 2 and 7, but by day 12 its expression had fallen back to basal
levels. A similar pattern of expression was seen for A2BR mRNA
during osteoblastogenesis, but the increase in protein level
persisted beyond that of the mRNA, probably because the
protein signal is sustained after the mRNA had been degraded.
Effects of adenosine receptor agonists on cAMP
accumulation
Treatment with adenosine (natural ligand) and NECA (universal
agonist) increased cAMP accumulation in a dose-related manner
at all time points, indicating the predominance of A2Rs at all
stages of osteoblastogenesis (see Fig. 2G, H for day 9 time point).
When compared with undifferentiated MSCs (day 0), the
efficiency of adenosine and NECA in stimulating cAMP
production increased during the time of osteoblastic induction.
On day 0, adenosine (104M) stimulated cAMP levels ninefold,
and this was increased to 153-fold (p< .001) after 9 days of
differentiation. The efficacy of NECA to increase cAMP also was
increased significantly from 25-fold in MSCs to 275-fold at 9 days
(p< .001) of osteoblastogenesis (Fig. 2H). Furthermore, MRS1706
(106M) significantly reduced NECA (105M) stimulated cAMP
accumulation (19.4-fold reduced to 11.6-fold, respectively,
p< .001) on day 9 of osteoblastogenesis. In addition,
SCH442416 (106M) significantly (p< .001) reduced this effect
of NECA (21.2-fold reduced to 13.1-fold with SCH442416).
CGS21680 (A2AR agonist) had little effect on cAMP expression
in undifferentiated MSCs (Fig. 2I), suggesting an absence
of A2AR. On osteoblastic induction, however, CGS21680
significantly stimulated cAMP production, with maximum
efficacy on day 9 (p< .001; Fig. 2I). During osteoblastogenesis,
although we have shown an increase in A2AR expression, the
observed maximal stimulation of cAMP accumulation by
NECA was approximately 20-fold more than that seen with
CGS21680 at all time points. Together, these data indicate
that A2AR and A2BR expression increased during osteoblastogen-
esis of MSCs and concur with previous data showing increased
mRNA and protein expression. Nevertheless the A2BR remained
as the dominant receptor in MSC-derived osteoblasts. Further-
more, CCPA did not affect forskolin-stimulated cAMP production
(results not shown).
Effects of adenosine receptor agonists and antagonists
on osteoblast markers during the differentiation of
MSCs to osteoblasts
All the osteoblast markers examined (ie, Runx2, ALP, collagen
type 1, and osteocalcin) increased during induced osteoblasto-
genesis of MSCs, and Runx2 and ALP expression increased even
further in the presence of NECA (106M). Runx2 mRNA was
increased fourfold on day 7 and was further enhanced by NECA
to sevenfold (Fig. 3A; p< .05). Adenosine, however, had no effect.
Both NECA (Fig. 3B) and adenosine (results not shown)
stimulated ALP mRNA expression, but neither had a significant
effect on the expression of collagen type 1 or osteocalcin mRNA.
The late osteoblast marker, osteocalcin, however, showed a
particularly large change during osteoblastogenesis, with a
greater than 10,000-fold increase in mRNA after 7 days.
Initial cell number experiments with receptor antagonists
(ie, A2AR, SCH442416, and A2BR, MRS1706) demonstrated that
concentrations up to 106M were without effect. These
concentrations were used subsequently, and exposure to
antagonists alone for 2 or 5 days did not induce significant
changes in ALP expression (Fig. 3C). In the presence of either
SCH442416 or MRS1706, however, the NECA-induced increase in
ALP expression was significantly reduced (p< .01).
Effects of adenosine receptor agonists and antagonists
on ALP enzyme activity
In addition to effects on ALP mRNA expression, NECA (Fig. 3D)
and adenosine (results not shown) both induced a dose-
dependent increase in ALP enzyme activity over 5 to 7 days of
osteoblast differentiation. The effects of NECA occurred earlier
(day 2) and appeared more potent than those of adenosine,
probably a reflection of the stability of NECA in comparison with
adenosine. Beyond day 7 of agonist exposure, NECA and
adenosine had little effect on ALP enzyme activity. Similar
stimulatory effects on ALP enzyme activity were seen with the
CGS21680 (Fig. 3E); interestingly, this increase in enzyme activity
seemed to persist for up to at least 12 days. CCPA did not
modulate ALP enzyme activity.
When receptor antagonists (ie, A2AR, SCH442416,
and A2BR, MRS1706) were used, exposure to antagonists alone
for 2 or 5 days did not induce significant changes in ALP enzyme
activity (Figs. 2G and 3F). In the presence of SCH442416,
however, NECA-induced ALP enzyme activity was partially
(75%) but significantly reversed (p< .001; Fig. 3F). In addition,
the A2BR antagonist MRS1706 abolished the increase in ALP
mRNA expression and ALP enzyme activity induced by NECA on
days 2 and 5 of differentiation (Fig. 3G).
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Effects of adenosine receptor agonists and antagonists
on mineralization of MSC-derived osteoblasts
Since A2AR and A2BR seemed to play an important role in
osteoblastogenesis, we also investigated whether activation of
these receptors stimulated matrix mineralization. Moderate
alizarin red S staining was observed in untreatedMSCs after 10 to
12 days, and this was further enhanced (p< .001), respectively,
by 109%, 50%, and 37% with adenosine (104M), adenosine
(105M), or NECA (105M) (Figs. 2I and 3H and results not
shown). Mineralization, however, was unaffected by lower
concentrations of NECA or adenosine. Surprisingly, CGS21680
(previously shown to induce ALP enzyme activity) had no effect
on mineralization (Supplemental Fig. S1), and mineralization also
was unaffected by the A1R agonist CCPA (Supplemental Fig. S1).
The A2BR antagonist MRS1706 inhibited the increase in
mineralization induced by adenosine by up to 95% (p< .001;
Fig. 3I), whereas the A2AR antagonist SCH442416 had no effect
(Supplemental Fig. S2). The lack of effect by CGS21680 and the
lack of inhibition of adenosine-induced mineralization by
SCH442416 suggest that the A2BR was responsible for the
induction of mineralization.
Adenosine receptor mRNA and protein expression
during adipogenesis
During adipogenesis, A1R mRNA expression was strongly
upregulated with an 800-fold increase on day 12 (p< .001).
Changes in A2ARmRNA paralleled those of A1R but only showed a
15- to 20-fold increase at 12 days (p< .001). There were no
changes in the expression of A2BR, A3R (Fig. 4C, D), CD73, or
adenosine deaminase (results not shown) during adipogenesis.
Fig. 3. Adenosine receptor signal pathway stimulation of osteogenesis in MSCs. mRNA expression of (A) Runx2 and (B) ALP following treatment with NECA
(106M) for 2 and 7 days. (mean SEM of three experiments in duplicate). p< .05 and p< .001 when compared with day 0. #p< .05 when compared
with vehicle at the same time point. (C) ALPmRNA expression following treatment with 106M SCH442416 andMRS1706 alone or in the presence of NECA
(106M) for 2 and 5 days (mean SEM of three experiments in duplicate). p< .001 when comparedwith untreated cells. ##p< .01 when comparedwith
NECA-treated cells at the same time point. (D, E) ALP activity following treatment with NECA and CGS21680 for 2, 5, 7, 9, and 12 days (mean SEM of three
experiments in quadruplicate). p< .05, p< .01, and p< .001 when compared with vehicle at the same time point. ( F, G) ALP activity following
treatment with 106M SCH442416 or MRS1706 alone or in combination with NECA (106M) (mean SEM of three experiments in quadruplicate).
p< .001 when compared with untreated cells. ###p< .001 when comparedwith NECA alone–stimulated cells at the same time point. (H, I) Mineralization
of MSCs following treatment with adenosine (104M) alone or in combination with 106M to 107M MRS1706. (H) Representative photograph [control
(c), adenosine (104M, a), adenosine (104M)þMRS1706 (107M) (a), and adenosine (104M)þMRS 1706 (106M) (a^)]. (I) Mineralization results
following elution of alizarin red S and spectrophotometric measurement. (Mean SEM from three experiments in triplicate). p< .001 when compared
with vehicle control. ##p< .001 and ###p< .001 when compared with adenosine-stimulated.
ADENOSINE AND MSC DIFFERENTIATION Journal of Bone and Mineral Research 2117
Representative Western blots for A1R, A2AR, and A2BR protein
expression during adipogenesis (Fig. 4E) showed that in parallel
with changes in mRNA expression, A1R and A2AR protein expres-
sion also increased. There were no changes in A2BR protein
expression (confirmed by combining densiometry values from
three experiments) during adipogenesis, consistent with a lack of
change in its mRNA.
Adenosine-mediated cAMP responses during
adipogenesis
Figure 4F–I shows the changes in cAMP when MSCs were grown
with or without differentiation medium for 9 days. At 104M, the
fold increases in cAMP for MSCs and adipocytes were,
respectively, 10- and 37-fold (adenosine; p< .001), 25- and 55-
fold (NECA; p< .001), and 0- and 8-fold (CGS21680; p< .001).
Although these data indicate an overall increase in A2R function
in adipocytes compared with undifferentiated MSCs, the relative
change in response to CGS21680 was particularly noticeable and
is consistent with an increase in A2AR mRNA and A2AR protein
on adipocyte differentiation. Furthermore, MRS1706 and
SCH442416 significantly inhibited cAMP responses to NECA
(19.4-fold with 105M NECA reduced to 11.6-fold with 106M
MRS1706 and 18.1-fold with 105M NECA reduced to 7.4-fold
with 106M SCH442416 (both p< .001).
Although there was a large increase in A1R mRNA during
adipogenesis, this did not appear to be translated into protein,
where only a small increase was observed. The A1R agonist CCPA
failed to have an inhibitory action on forskolin-stimulated cAMP
levels in either MSCs or adipocyte-differentiated MSCs; this
suggests low expression of the A1R, particularly in the context of
increased A2AR expression.
Effects of adenosine and NECA on lipid accumulation and
adipocyte numbers
Treatment with NECA (104M) increased, in a time-dependent
manner, the size and number of cells that contained lipid
(Fig. 5A). Following elution of the oil red O (a measure of total
lipid content of the culture; Fig. 5B), the observed effects of NECA
(104M to 106M) were dose-dependent, 106M being the
lowest concentration that caused a significant (p< .01)
response. Adenosine (Supplemental Fig. S3) had less of an
effect in comparison with NECA, and this probably reflects the
short half-life, whereas NECA is regarded as being relatively
stable. Treatment with adenosine (104M) significantly (p< .01)
increased adipogenesis from day 7, with the maximum effect on
day 12. Nile red staining, however, showed that the number of
adipocytes increased by up to 100% (p< .001) in the presence of
NECA (104M; results not shown).
Effect of NECA on the expression of adipocyte markers as
MSCs differentiated to adipocytes
Adipogenic differentiation resulted in a gradual increase in the
mRNA expression of PPARg, C/EBPa, and LPL mRNA, which was
further enhanced by the addition of NECA (Fig. 5C–E). PPARg
mRNA expression was induced significantly from 3-, 7-, and 10-
fold in untreated MSCs to 6- (p< .05), 21- (p< .001), and 31-fold
(p< .01) in the presence of 104M NECA for 2, 7, and 12 days,
respectively. Treatment with 105M NECA also tended to have a
similar stimulatory effect, although statistical significance was
not reached. NECA also induced similar but more pronounced
changes in C/EBPa and LPL mRNA expression.
Effect of selective adenosine receptor agonists and
antagonists on lipid accumulation
Since our experiments suggested that the differentiation of MSCs
to adipocytes was associated with changes in expression and
activation of A2AR and A1R, the effects of CCPA and CGS21680 on
adipogenesis also were investigated. Both compounds stimulat-
ed adipogenesis in a time- and dose-related fashion (Fig. 6A, B).
There were small but significant increases in adipogenesis in the
presence of CCPA at 5, 7, and 9 days but only at the higher
concentrations (105 and 106M). Similar concentrations of
CGS21680 had amuchmore pronounced effect on adipogenesis.
The effects of CGS21680 were comparable to those observed
when NECA was used (Fig. 5A, B). These results indicate an
involvement of A1R and A2AR in the adipogenic differentiation of
Table 1. Primer Sequences
Primers (all 5’!3’) Forward Reverse Product size (bp)
A1R ATTGCTGTGGATCGATACC GAATCCAGCAGCCAGCTAT 100
A2AR CTTCGCTATCACCATCAGCA AAATTGCAATGATGCCCTTC 200
A2BR TCCATCTTTAGCCTCTTG TCCTCTTGCTCGTGTTC 100
A3R TTCTTGTTTGCCTTGTGCTG AGGGTTCATCATGGAGTTCG 129
CD73 GGACTGATTGATCCCCTCCT TTGTCCCTGGATTTGAGAGG 192
Adenosine deaminase AAGGAGACCTCACCCCTGAT GTCTCATCCCCAGCCAAGT 198
Runx2 GGCCCTGGTGTTTAAATGGT AGGCTGTTTGACGCCATAGT 178
ALP CTGCAAGGACATCGCCTATC CATCAGTTCTGTTCTTGGGGTA 101
Osteocalcin CCTTCATGTCCAAGCAGGAG GTCCGCTAGCTCGTCACAAT 152
PPARg TTCAGAAGTGCCTTGCTGTG CCAACAGCTTCTCCTTCTCG 84
C/EBPa GCCAAGAAGTCGGTGGATAA AACACCTTCTGCTGCGTCTC 125
LPL CTTCAACCACAGCAGCAAAA GGCCCGATACAACCAGTCTA 148
b-Actin TGTCACCAACTGGGACGATA GGGGTGTTGAAGGTCTCAAA 165
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MSCs. To confirm the involvement of these two receptors, the
selective antagonists PSB36 (A1R) and SCH442416 (A2AR) were
incubated together with NECA (Fig. 5C). The concentrations of
antagonist used were 106M or less because higher concentra-
tions caused a reduction in cell number. Addition of PSB36 or
SCH442416 alone (106 and 107M) had no effect on lipid
accumulation. PSB36, however, had no effect on the stimulation
of adipogenesis by NECA, suggesting that A1R may not have an
important role in adenosine-mediated adipogenesis. On the
other hand, SCH442416 (106 and 107M) inhibited NECA
stimulation of lipid accumulation by 80% (p< .001) and 75%
(p< .01), respectively, after 12 days of treatment (Fig. 6C). This
inhibitory action of SCH442416, however, was not seen at 7 days.
Effects of adenosine receptor overexpression on
osteogenic- and adipogenic-associated genes in MSCs
Transient overexpression of A1R, A2AR, and A2BR in MSCs
revealed significant changes in expression of osteoblasts and
adipocyte markers (Fig. 7A–D). Specifically, in relation to
osteoblast markers, A2BR overexpression increased the expres-
sion of the early marker Runx2 (p< .001; Fig. 7A), whereas A1R
Fig. 4. Expression and function of adenosine receptors during the differentiation of MSCs into adipocytes. mRNA expression of (A) A1R, (B) A2AR, (C) A2BR,
and (D) A3R (mean SEM of three experiments in duplicate). (E) Representative Western blots probed for A1R, A2AR, and A2BR. (F–H) cAMP concentrations
following incubation with ( F) adenosine, (G) NECA, (H) CGS21680, and (I) CCPA for 15minutes in the presence of RO20-1724 (104M) (mean SEMof three
experiments in quadruplicate).p< .05, p< .01, and p< .001 when compared with untreated cells; ###p< .001 when compared with MSCs stimulated
with the same concentration of agonist.
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overexpression decreased the expression of the intermediate
marker ALP (Fig. 7B). This latter observation could indicate
that the A1R influences differentiation of MSCs to adipocytes
and thus away from the osteoblast lineage and therefore ties in
with our other data. Overexpression of A1R or A2BR did
not change the expression of adipocyte markers (ie, PPARg
and C/EBPa; Fig. 7C, D). However, overexpression of the A2AR
significantly increased the expression of PPARg (p< .01; Fig. 7C)
and C/EBPa (p< .001; Fig. 7D).
Discussion
There has been increasing interest recently in determining the
factors that regulate the differentiation of MSCs into osteoblasts
and adipocytes. Such information would enable the develop-
ment of strategies for treating diseases associated with an
imbalance in the differentiation and function of these lineages.
Adenosine is known to regulate the physiologic function of many
cells by binding to cell membrane receptors. Under basal
conditions, adenosine concentrations in cells and tissue fluids
are low (30 to 300 nM). When cells become stressed (eg, during
hypoxic events, inflammation, and tissue injury), however, there
is an accumulation of adenosine in the extracellular space(25,26)
resulting in concentrations of 30mM.(25,27) Adenosine receptors
are known to be expressed by MSCs and are important for the
function of these cells.(14,19) In addition, MSCs are capable of
producing adenosine because they all express CD73.(28)
Recently, adenosine also has been shown to help the localization
of human MSCs and promote their differentiation into
hepatocyte-like cells,(29) suggesting that adenosine also has a
role in the differentiation of MSCs into several possible lineages.
Thus we have explored how adenosine receptors are modulated
as MSCs are induced to differentiate into osteoblasts and
adipocytes and how these processes may be influenced by
adenosine.
Fig. 5. NECA stimulation of adipogenesis of MSCs. Lipid accumulation (A) visualized by staining with oil red O (200) (NECA 104M compared with
control) and (B) quantified by measuring the absorbance of the dye retained by the cells at 490 nm (mean SEM of three experiments in triplicate).
p< .05, p< .01, and p< .001 when comparedwith control at the same time point. (C) PPARg, (D) C/EBPa, and (E) LPLmRNA expression followingNECA
treatment in adipogenicmedium (mean SEM of three experiments in duplicate). p< .05, p< .01, and p< .001 when comparedwith day 0 (assigned
a value of 1). #p< .05, ##p< .01, and ###p< .001 when compared with vehicle at the same time point.
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In undifferentiated MSCs, the A2BR was dominantly expressed.
Furthermore, its activation (unpublished observations) or over-
expression in undifferentiated cells was sufficient to promote the
expression of osteoblast lineage markers. Interestingly, A2BR
gene and protein expression appeared to be transiently
upregulated as cells differentiated into osteoblasts, suggesting
that this receptor may have a role in early osteoblastic
differentiation. On the other hand, A2AR gene and protein
expression appeared to increase during later stages of
osteoblastic differentiation. From these data, one can speculate
that A2BRs are more important for commitment and differentia-
tion to osteoblasts and that A2ARs are important for osteoblast
maturation andmaintenance of the osteoblast phenotype. There
also was a progressive increase in A2AR-mediated cAMP
expression as MSCs were induced to differentiate to osteoblasts,
which also may support a role for this receptor in later
differentiation or function of osteoblasts. Activation (unpub-
lished observations) or overexpression of A2AR in fact did not
alter the expression of Runx2 or ALP in undifferentiated MSCs,
whereas it stimulated osteogenesis during the differentiation. In
addition, A2AR has been implicated in many activities by mature
osteoblasts, which might explain the upregulation of the
receptors following osteogenesis.(30,31) Nevertheless, in our
study, A2BR was the dominant receptor throughout the
differentiation process, and its activation led to a stimulation
of osteoblastogenesis and subsequent mineralization by
osteoblasts. Our observations are supported by a recent
publication by Larsen and colleagues,(32) who show that
the A2BR is upregulated by 4.2-fold in a human bone marrow
stromal cell population capable of in vivo heterotropic bone
formation when compared with a second population that does
not have the capacity to form such bone.
The A1R, in contrast to the A2BR, was found to be involved in
adipogenesis and adipocyte function. A1R expression is reported
to be low in preadipocytes but increases on adipogenesis and
remains at high levels in mature adipocytes.(20,21,33) Our data
Fig. 6. A1R and A2AR receptor activation promotes the adipogenesis of MSCs. MSCs incubated with adipogenic medium in the presence of (A) CCPA and
(B) CGS21680 and lipid accumulation visualized by light microscopy of oil red O staining (200) and quantified by measuring the absorbance at 490 nm
(mean SEM of three experiments in triplicate). (C) Lipid accumulation in MSCs treated with SCH442416 at 106M and 107M in the presence or absence
of NECA (105M) in adipogenic medium (mean SEM of four experiments in triplicate). p< .05, p< .01, and p< .001 when compared with vehicle at
the same time point; ##p< .01 and ###p< .001 when compared with NECA-stimulated cultures at the same time point.
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concur with these findings. We showed that expression of
the A1R in rat MSCs was low and that it increased markedly on
differentiation to adipocytes. A1RmRNA expression increased by
more than 800-fold as MSCs were induced to differentiate to
adipocytes. This was accompanied by increases (but to a much
lesser extent) in protein expression. On the other hand, when
MSCs were differentiating to osteoblasts, there was a less than
fivefold increase in A1R mRNA and no change in protein
expression. Despite the remarkable increase in expression during
adipocyte differentiation, A1R activation by the selective agonist
CCPA had no effect on expression of markers of adipogenesis. A
similar result was observed when MSCs were transfected with
the A1R gene. However, CCPA was found to elevate lipid
accumulation by MSCs owing to either stimulation of lipogenesis
or inhibition of lipolysis. Adenosine, acting through the A1R, has
been implicated in many of the physiologic functions of
adipocytes and has been associated in particular with an
inhibition of lipolysis.(34) Many A1R agonists have been shown to
induce antilipolytic effects.(33,35,36) Furthermore, overexpression
of A1Rs and subsequent inhibition of lipolysis in adipocytes have
been suggested as a potential cause of a lower and slower rate of
weight loss in obese African-American women.(37) We also have
evidence that the A1R stimulates lipogenesis during the
differentiation of a preosteoblast cell line into adipocytes
(unpublished observations).
Adipocyte differentiation of MSCs also was unexpectedly
accompanied by increases in A2AR expression at both the mRNA
and protein levels. This was surprising because others have
reported a loss of A2R expression and function during
adipogenesis of a preadipocyte cell line (Ob1771)(21) or failed
to detect A2R expression in primary mature adipocytes.
(20)
Increases in A2AR mRNA and protein expression on induced
adipogenesis also was supported by increases in cAMP
stimulation in response to adenosine, NECA, and
the A2AR agonist CGS21680. The importance of the cAMP/
PKA/CREB pathway in the induction of adipocyte differentiation
and maturation has been known for many years. Indeed, the
cAMP pathway has been reported previously, in murine
preadipocyte 3T3-L1 cells and in human MSCs, to stimulate
adipogenesis and expression of adipocytic genes.(38,39) Other
relevant observations are that adipocyte differentiation inmouse
embryonic fibroblasts from CREB/ mice is impaired,(40) and
siRNA-mediated depletion of CREB and the closely related
activating transcription factor 1 (ATF1) in 3T3-L1 cells results in
loss of adipogenic differentiation.(41)
Activation of A2AR by CGS21680 stimulated adipogenesis of
MSCs with similar potencies to NECA. The stimulatory affect of
NECA could be blocked by SCH442416 (A2AR-selective antago-
nist), suggesting an A2AR-dependent action. We also investigated
whether enhanced expression of A2AR is able to stimulate
adipogenesis or osteoblastogenesis in the absence of differenti-
ation medium. Our data show that enhanced expression
of A2AR is sufficient to induce the expression of key adipogenic
master switches such as PPARg and C/EBPa that are essential to
adipogenic differentiation.(42) Upregulation of these genes
subsequently leads to an increase in differentiation, lipid
accumulation, and activities of adipocytes. Enhanced A1R and
A2BR expression, on the other hand, did not effect the expression
Fig. 7. Effects of adenosine receptor overexpression on osteogenic- and adipogenic-associated genes in MSCs. MSCs were transfected with positive
control (pmaxGFP) and PCDNA3 plasmids containing adenosine receptor genes (A1R, A2AR, and A2BR). Relative levels of (A) Runx2, (B) ALP, (C) PPARg, and (D)
C/EBPa mRNA compared with plasmid only–containing cells (mean SEM of three experiments in duplicate). p< .05, p< .01,and p< .001 when
compared with values for control at the same time point.
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of PPARg and C/EBPa. These findings suggest that the A2AR is
mainly associated with the differentiation of MSCs into
adipocytes, whereas the A1R could be involved in lipogenic
activity of adipocytes rather than their differentiation.
In summary, data presented here show that adenosine can be
important for both osteoblast and adipocyte differentiation.
The A2BR is the dominant subtype in undifferentiated MSCs and
during osteoblastogenesis. Osteoblast differentiation is associ-
ated with increases in the A2AR and A2BR expression, and these
receptors stimulate osteoblast differentiation. The A2BR in
particular is the major subtype in the differentiation process
because it enhances the three stages of initiation, maturation,
and mineralization in osteoblastogenesis of MSCs. On the other
hand, the adenosine receptors involved in adipogenesis of MSCs
are A2AR and A1R. Despite most of the receptor subtypes being
expressed in most, but not all, tissues, targeting adenosine
receptors in pathophysiology with truly specific compounds is
still a distinct possibility. Many serious attempts are currently
being undertaken to develop new therapies in this field—for
example, several companies are working in late clinical trial
with A2AR antagonists for neurodegeneration.
(13) Our work
presents a better understanding of adenosine receptor
expression and function in MSCs, and the changes in expression
and effects of activation of A1R, A2AR, and A2BR observed
make them promising targets for developing drugs to prevent
or treat conditions with insufficient bone or excessive
adipocyte formation. Even if these drugs could not be used
systemically, their use locally at fracture sites, in osteoarthritic
joints, or to prime MSCs at the time of replacement in relation to
tissue engineering, for example, is a distinct possibility.
Furthermore, it may be possible to target adenosine receptors
indirectly by modulating downstream effectors such as ion
channels(43) or putative interacting proteins such as glutamate
receptors.
Disclosures
All the authors state that they have no conflicts of interest.
Acknowledgments
We acknowledge the School of Medicine, Cardiff University, for
funding and technical assistance from Dr MD Lewis and Mrs C
Elford. BG and BAJE also thank theWilliamMorgan Thomas Fund,
Cardiff University for financial support.
Author’s roles: BG was involved with conception and design,
collection and/or assembly of data, data analysis and interpreta-
tion, manuscript writing, and final approval of the manuscript.
AAA was involved with collection of data and data analysis for
the revised manuscript. JH was involved with conception and
design, financial support, provision of study material or patients,
data analysis and interpretation, manuscript writing, and final
approval of the manuscript. BAJE was involved with conception
and design, financial support, provision of study material or
patients, data analysis and interpretation, manuscript writing,
and final approval of the manuscript.
References
1. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the
obesity of bone? Nat Clin Pract Rheum. 2006;2:35–43.
2. Kawai M, Rosen CJ. Bone: adiposity and bone accrual—still an
established paradigm? Nat Rev Endocrinol. 2010;6:63–64.
3. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol
Med. 2001;226:507–520.
4. Blair HC, Zaidi M, Schlesinger PH. Mechanisms balancing skeletal
matrix synthesis and degradation. Biochem J. 2002;364:329–341.
5. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators.
J Cell Biochem. 2006;98:1076–1084.
6. Huang W, Yang SY, Shao JZ, Li YP. Signaling and transcriptional
regulation in osteoblast commitment and differentiation. Front
Biosci. 2007;12:3068–3092.
7. Otto TC, Lane MD. Adipose Development: From Stem Cell to Adipo-
cyte. Crit Rev Biochem Mol. 2005;40:229–242.
8. Di Iorgi N, Rosol M, Mittelman SD, Gilsanz V. Reciprocal Relation
between Marrow Adiposity and the Amount of Bone in the Axial and
Appendicular Skeleton of Young Adults. J Clin Endocrinol Metab.
2008;93:2281–2286.
9. Di Iorgi N, Mo AO, Grimm K, Wren TAL, Dorey F, Gilsanz V. Bone
Acquisition in Healthy Young Females Is Reciprocally Related to
Marrow Adiposity. J Clin Endocrinol Metab. 2010;95:2977–2982.
10. Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ. Adipocytic
proportion of bone marrow is inversely related to bone formation in
osteoporosis. J Clin Pathol. 2002;55:693–698.
11. Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM, KassemM.
Patients With High Bone Mass Phenotype Exhibit Enhanced
Osteoblast Differentiation and Inhibition of Adipogenesis of Human
Mesenchymal Stem Cells. J Bone Miner Res. 2007;22:1720–1731.
12. Valentin D, Aline M, Lafage-Proust M-H, et al. Mechanical Loading
Down-Regulates Peroxisome Proliferator-Activated Receptor g in
Bone Marrow Stromal Cells and Favors Osteoblastogenesis at the
Expense of Adipogenesis. Endocrinology. 2007;148:2553–2562.
13. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res.
2010;316:1284–1288.
14. Evans BAJ, Elford C, Pexa A, et al. Human Osteoblast Precursors
Produce Extracellular Adenosine, Which Modulates Their Secretion of
IL-6 and Osteoprotegerin. J Bone Miner Res. 2006;21:228–236.
15. Montesinos MC, Gadangi P, Longaker M, et al. Wound healing is
accelerated by agonists of adenosine A(2) (G(alphas)-linked) recep-
tors. J Exp Med. 1997;186:1615–1620.
16. Linden J. Molecular approach to adenosine receptors: Receptor-
Mediated Mechanisms of Tissue Protection. Ann Rev Pharmacol.
2001;41:775–787.
17. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors
in downregulation of inflammation and protection from tissue
damage. Nature. 2001;414:916–920.
18. Montesinos MC, Desai A, Chen J-F, et al. Adenosine Promotes Wound
Healing and Mediates Angiogenesis in Response to Tissue Injury
Via Occupancy of A2A Receptors. Am J Pathol. 2002;160:2009–
2018.
19. Katebi M, Soleimani M, Cronstein BN. Adenosine A2A receptors play
an active role in mouse bone marrow-derived mesenchymal stem
cell development. J Leukocyte Biol. 2009;85:438–444.
20. Vassaux G, Gaillard D, Mari B, Ailhaud G, Negrel R. Differential
Expression of Adenosine-A1 and Adenosine-A2 Receptors in Prea-
dipocytes and Adipocytes. Biochem Biophysl Res Co. 1993;193:1123–
1130.
21. Børglum JD, Vassaux G, Richelsen B, et al. Changes in adenosine
A1- and A2-receptor expression during adipose cell differentiation.
Mol Cell Endocrinol. 1996;117:17–25.
ADENOSINE AND MSC DIFFERENTIATION Journal of Bone and Mineral Research 2123
22. Rice AM, Fain JN, Rivkees SA. A1 Adenosine Receptor Activation
Increases Adipocyte Leptin Secretion. Endocrinology. 2000;141:
1442–1445.
23. Dong Q, Ginsberg HN, Erlanger BF. Overexpression of the A1
adenosine receptor in adipose tissue protects mice from obesity-
related insulin resistance. Diabetes Obes Metab. 2001;3:360–
366.
24. Sen A, Lea-Currie YR, Sujkowska D, et al. Adipogenic potential of
human adipose derived stromal cells from multiple donors is het-
erogeneous. J Cell Biochem. 2001;81:312–319.
25. Pastor-Anglada M, Casado FJ, Valdes R, Mata J, Garcia-Manteiga J,
Molina M. Complex regulation of nucleoside transporter expression
in epithelial and immune system cells. Mol Membr Biol. 2001;18:81–
85.
26. Hyde RJ, Cass CE, Young JD, Baldwin SA. The ENT family of eukaryote
nucleoside and nucleobase transporters: recent advances in the
investigation of structure/function relationships and the identifica-
tion of novel isoforms. Mol Membr Biol. 2001;18:53–63.
27. Latini S, Pedata F. Adenosine in the central nervous system: release
mechanisms and extracellular concentrations. J Neurochem. 2001;
79:463–484.
28. Ferro F, Falini G, Spelat R, et al. Biochemical and biophysical analyses
of tissue-engineered bone obtained from three-dimensional culture
of a subset of bone marrow mesenchymal stem cells. Tissue Eng Part
A. 2010;16:3657–3667.
29. Mohamadnejad M, Sohail MA, Watanabe A, Krause DS, Swenson ES,
Mehal WZ. Adenosine inhibits chemotaxis and induces hepatocyte-
specific genes in bone marrowmesenchymal stem cells. Hepatology.
2010;51:963–973.
30. Russell J, Stephenson G, Yellowley C, Benton H. Adenosine
Inhibition of Lipopolysaccharide-Induced Interleukin-6 Secretion
by the Osteoblastic Cell Line MG-63. Calcif Tissue Int. 2007;81:
316–326.
31. Fatokun AA, Stone TW, Smith RA. Hydrogen peroxide-induced
oxidative stress in MC3T3-E1cells: The effects of glutamate and
protection by purines. Bone. 2006;39:542–551.
32. Larsen KH, Frederiksen CM, Burns JS, Abdallah BM, Kassem M.
Identifying a molecular phenotype for bone marrow stromal cells
with in vivo bone-forming capacity. J Bone Miner Res. 2010;25:796–
808.
33. Fatholahi M, Xiang Y, Wu Y, et al. A Novel Partial Agonist of the A1 -
Adenosine Receptor and Evidence of Receptor Homogeneity in
Adipocytes. J Pharmacol Exp Ther. 2006;317:676–684.
34. Dhalla AK, Chisholm JW, Reaven GM, Belardinelli L. A1 Adenosine
Receptor: Role in Diabetes and Obesity. Handb Exp Pharmacol.
2009;193:271–295.
35. Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L. Pharmacology
and Therapeutic Applications of A1 Adenosine Receptor Ligands.
Curr Top Med Chem. 2003;3:369–385.
36. Dhalla AK, Santikul M, Smith M, Wong M-Y, Shryock JC, Belardinelli L.
Antilipolytic Activity of a Novel Partial A1 Adenosine Receptor Ago-
nist Devoid of Cardiovascular Effects: Comparisonwith Nicotinic Acid.
J Pharmacol Exp Ther. 2007;321:327–333.
37. Barakat H, Davis J, Lang D, Mustafa SJ, McConnaughey MM. Differ-
ences in the Expression of the Adenosine A1 Receptor in Adipose
Tissue of Obese Black and White Women. J Clin Endocrinol Metab.
2006;91:1882–1886.
38. Petersen RK, Madsen L, Pedersen LM, Hallenborg P, Hagland H, Viste
K, Doskeland SO, Kristiansen K. Cyclic AMP (cAMP)-mediated stimu-
lation of adipocyte differentiation requires the synergistic action of
Epac- and cAMP-dependent protein kinase-dependent processes.
Mol Cell Biol. 2008;28:3804–3816.
39. Yang D-C, Tsay H-J, Lin S-Y, Chiou S-H, Li M-J, Chang T-J, Hung S-C.
cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/
OPG mRNA expression in mesenchymal stem cells by suppressing
leptin. PLoS One. 2008;3:e1540.
40. Zhang J-W, Klemm DJ, Vinson C, Lane MD. Role of CREB in transcrip-
tional regulation of CCAAT/enhancer-binding protein b gene during
adipogenesis. J Biol Chem. 2004;279:4471–4478.
41. Fox KE, Fankell DM, Erickson PF, Majka SM, Crossno JT Jr, Klemm DJ.
Depletion of cAMP-response element-binding protein/ATF1 inhibits
adipogenic conversion of 3T3-L1cells ectopically expressing CCAAT/
enhancer-binding protein (C/EBP) alpha, C/EBP beta, or PPAR gam-
ma2. J Biol Chem. 2006;281:40341–40353.
42. Muruganandan S, Roman A, Sinal C. Adipocyte differentiation of
bone marrow-derived mesenchymal stem cells: Cross talk with the
osteoblastogenic program. Cell Mol Life Sci. 2009;66:236–253.
43. Henney NC, Li B, Elford C, et al. A large-conductance (BK) potassium
channel subtype affects both growth and mineralization of human
osteoblasts. Am J Physiol Cell Physiol. 2009;97:C1397–1408.
2124 Journal of Bone and Mineral Research GHARIBI ET AL.
